Annual CFO
-$8.85 M
+$6.37 M+41.83%
31 December 2023
Summary:
GT Biopharma annual cash flow from operations is currently -$8.85 million, with the most recent change of +$6.37 million (+41.83%) on 31 December 2023. During the last 3 years, it has fallen by -$1.59 million (-21.89%). GTBP annual CFO is now -2313.00% below its all-time high of $400.00 thousand, reached on 31 December 1994.GTBP Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$2.74 M
+$799.00 K+22.60%
30 September 2024
Summary:
GT Biopharma quarterly cash flow from operations is currently -$2.74 million, with the most recent change of +$799.00 thousand (+22.60%) on 30 September 2024. Over the past year, it has dropped by -$773.00 thousand (-39.36%). GTBP quarterly CFO is now -647.40% below its all-time high of $500.00 thousand, reached on 31 March 1994.GTBP Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$12.48 M
-$773.00 K-6.60%
30 September 2024
Summary:
GT Biopharma TTM cash flow from operations is currently -$12.48 million, with the most recent change of -$773.00 thousand (-6.60%) on 30 September 2024. Over the past year, it has dropped by -$1.38 million (-12.43%). GTBP TTM CFO is now -1883.29% below its all-time high of $700.00 thousand, reached on 30 September 1994.GTBP TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTBP Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.8% | -39.4% | -12.4% |
| 3 y3 years | -21.9% | +30.3% | +9.7% |
| 5 y5 years | +17.1% | -143.1% | -182.6% |
GTBP Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -21.9% | +43.3% | -41.5% | +47.5% | -41.0% | +27.2% |
| 5 y | 5 years | -141.9% | +43.3% | -1127.3% | +47.5% | -327.4% | +27.2% |
| alltime | all time | -2313.0% | +43.3% | -647.4% | +47.5% | -1883.3% | +27.2% |
GT Biopharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.74 M(-22.6%) | -$12.48 M(+6.6%) |
| June 2024 | - | -$3.54 M(-15.1%) | -$11.71 M(+15.8%) |
| Mar 2024 | - | -$4.16 M(+103.4%) | -$10.11 M(+14.2%) |
| Dec 2023 | -$8.85 M(-41.8%) | -$2.05 M(+4.2%) | -$8.85 M(-20.3%) |
| Sept 2023 | - | -$1.96 M(+1.5%) | -$11.10 M(-7.9%) |
| June 2023 | - | -$1.94 M(-33.4%) | -$12.06 M(-6.6%) |
| Mar 2023 | - | -$2.91 M(-32.4%) | -$12.91 M(-15.2%) |
| Dec 2022 | -$15.22 M(-2.5%) | -$4.30 M(+47.3%) | -$15.22 M(+4.1%) |
| Sept 2022 | - | -$2.92 M(+4.7%) | -$14.62 M(-6.5%) |
| June 2022 | - | -$2.79 M(-46.6%) | -$15.63 M(-8.8%) |
| Mar 2022 | - | -$5.21 M(+40.8%) | -$17.14 M(+9.8%) |
| Dec 2021 | -$15.61 M(+114.9%) | -$3.71 M(-5.7%) | -$15.61 M(+12.9%) |
| Sept 2021 | - | -$3.93 M(-8.4%) | -$13.83 M(+19.2%) |
| June 2021 | - | -$4.29 M(+16.4%) | -$11.60 M(+8.2%) |
| Mar 2021 | - | -$3.68 M(+91.2%) | -$10.72 M(+47.7%) |
| Dec 2020 | -$7.26 M(+98.5%) | -$1.93 M(+13.3%) | -$7.26 M(+24.8%) |
| Sept 2020 | - | -$1.70 M(-50.1%) | -$5.82 M(+11.0%) |
| June 2020 | - | -$3.41 M(+1429.6%) | -$5.25 M(+79.6%) |
| Mar 2020 | - | -$223.00 K(-54.0%) | -$2.92 M(-20.2%) |
| Dec 2019 | -$3.66 M(-65.7%) | -$485.00 K(-56.9%) | -$3.66 M(-17.2%) |
| Sept 2019 | - | -$1.13 M(+3.6%) | -$4.42 M(-34.3%) |
| June 2019 | - | -$1.09 M(+13.1%) | -$6.72 M(-9.3%) |
| Mar 2019 | - | -$961.00 K(-22.7%) | -$7.41 M(-30.6%) |
| Dec 2018 | -$10.68 M(+96.6%) | -$1.24 M(-63.8%) | -$10.68 M(-7.8%) |
| Sept 2018 | - | -$3.43 M(+93.5%) | -$11.59 M(+11.5%) |
| June 2018 | - | -$1.77 M(-58.0%) | -$10.39 M(+15.4%) |
| Mar 2018 | - | -$4.23 M(+96.4%) | -$9.01 M(+65.9%) |
| Dec 2017 | -$5.43 M(+181.3%) | -$2.15 M(-3.8%) | -$5.43 M(+59.1%) |
| Sept 2017 | - | -$2.24 M(+472.1%) | -$3.41 M(+96.3%) |
| June 2017 | - | -$391.00 K(-39.8%) | -$1.74 M(-27.9%) |
| Mar 2017 | - | -$650.00 K(+381.5%) | -$2.41 M(+25.0%) |
| Dec 2016 | -$1.93 M(-58.6%) | -$135.00 K(-76.0%) | -$1.93 M(-29.5%) |
| Sept 2016 | - | -$563.00 K(-47.1%) | -$2.74 M(-2.5%) |
| June 2016 | - | -$1.06 M(+537.7%) | -$2.81 M(-7.5%) |
| Mar 2016 | - | -$167.00 K(-82.3%) | -$3.04 M(-34.8%) |
| Dec 2015 | -$4.66 M(+166.3%) | -$944.00 K(+49.1%) | -$4.66 M(-2.0%) |
| Sept 2015 | - | -$633.00 K(-51.0%) | -$4.75 M(+1.2%) |
| June 2015 | - | -$1.29 M(-27.6%) | -$4.70 M(+36.3%) |
| Mar 2015 | - | -$1.79 M(+72.2%) | -$3.45 M(+97.0%) |
| Dec 2014 | -$1.75 M(+295.7%) | -$1.04 M(+79.6%) | -$1.75 M(+61.9%) |
| Sept 2014 | - | -$578.00 K(+1244.2%) | -$1.08 M(+136.3%) |
| June 2014 | - | -$43.00 K(-52.2%) | -$457.00 K(+16.0%) |
| Mar 2014 | - | -$90.00 K(-75.6%) | -$394.00 K(-10.9%) |
| Dec 2013 | -$442.00 K(-55.2%) | -$369.00 K(-920.0%) | -$442.00 K(+54.0%) |
| Sept 2013 | - | $45.00 K(+125.0%) | -$287.00 K(-53.0%) |
| June 2013 | - | $20.00 K(-114.5%) | -$610.00 K(-34.6%) |
| Mar 2013 | - | -$138.00 K(-35.5%) | -$933.00 K(-5.5%) |
| Dec 2012 | -$987.00 K(+2.5%) | -$214.00 K(-23.0%) | -$987.00 K(-10.0%) |
| Sept 2012 | - | -$278.00 K(-8.3%) | -$1.10 M(+19.5%) |
| June 2012 | - | -$303.00 K(+57.8%) | -$918.00 K(-8.9%) |
| Mar 2012 | - | -$192.00 K(-40.7%) | -$1.01 M(+4.7%) |
| Dec 2011 | -$963.00 K(-37.3%) | -$324.00 K(+227.3%) | -$963.00 K(-5.2%) |
| Sept 2011 | - | -$99.00 K(-74.8%) | -$1.02 M(-22.3%) |
| June 2011 | - | -$393.00 K(+167.3%) | -$1.31 M(+10.5%) |
| Mar 2011 | - | -$147.00 K(-61.0%) | -$1.18 M(-22.9%) |
| Dec 2010 | -$1.53 M(+63.8%) | -$377.00 K(-3.3%) | -$1.53 M(-16.6%) |
| Sept 2010 | - | -$390.00 K(+45.0%) | -$1.84 M(+23.2%) |
| June 2010 | - | -$269.00 K(-46.1%) | -$1.49 M(+6.4%) |
| Mar 2010 | - | -$499.00 K(-26.8%) | -$1.40 M(+49.8%) |
| Dec 2009 | -$937.00 K(+454.4%) | -$682.00 K(+1450.0%) | -$937.00 K(+150.5%) |
| Sept 2009 | - | -$44.00 K(-75.4%) | -$374.00 K(-11.2%) |
| June 2009 | - | -$179.00 K(+459.4%) | -$421.00 K(+226.4%) |
| Mar 2009 | - | -$32.00 K(-73.1%) | -$129.00 K(-23.7%) |
| Dec 2008 | -$169.00 K | -$119.00 K(+30.8%) | -$169.00 K(-60.6%) |
| Sept 2008 | - | -$91.00 K(-180.5%) | -$429.00 K(+37.9%) |
| June 2008 | - | $113.00 K(-256.9%) | -$311.00 K(-5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$72.00 K(-81.0%) | -$328.00 K(+21.5%) |
| Dec 2007 | -$270.00 K(-59.8%) | -$379.00 K(-1503.7%) | -$270.00 K(+382.1%) |
| Sept 2007 | - | $27.00 K(-71.9%) | -$56.00 K(-135.7%) |
| June 2007 | - | $96.00 K(-785.7%) | $157.00 K(-178.5%) |
| Mar 2007 | - | -$14.00 K(-91.5%) | -$200.00 K(-70.2%) |
| Dec 2006 | -$671.00 K(-67.9%) | -$165.00 K(-168.8%) | -$671.00 K(-33.4%) |
| Sept 2006 | - | $240.00 K(-192.0%) | -$1.01 M(-41.1%) |
| June 2006 | - | -$261.00 K(-46.2%) | -$1.71 M(+1.0%) |
| Mar 2006 | - | -$485.00 K(-3.2%) | -$1.69 M(-19.1%) |
| Dec 2005 | -$2.09 M(+100.9%) | -$501.00 K(+8.2%) | -$2.09 M(+35.7%) |
| Sept 2005 | - | -$463.00 K(+89.8%) | -$1.54 M(+14.6%) |
| June 2005 | - | -$244.00 K(-72.4%) | -$1.35 M(-6.8%) |
| Mar 2005 | - | -$885.00 K(-1870.0%) | -$1.44 M(+38.6%) |
| Dec 2004 | -$1.04 M(+355.0%) | $50.00 K(-118.7%) | -$1.04 M(+5.0%) |
| Sept 2004 | - | -$267.00 K(-21.9%) | -$992.00 K(+12.3%) |
| June 2004 | - | -$342.00 K(-29.2%) | -$883.00 K(+40.6%) |
| Mar 2004 | - | -$483.00 K(-583.0%) | -$628.00 K(+174.2%) |
| Dec 2003 | -$229.00 K(-77.3%) | $100.00 K(-163.3%) | -$229.00 K(-24.4%) |
| Sept 2003 | - | -$158.00 K(+81.6%) | -$303.00 K(-46.8%) |
| June 2003 | - | -$87.00 K(+3.6%) | -$570.00 K(-10.4%) |
| Mar 2003 | - | -$84.00 K(-423.1%) | -$636.00 K(-36.9%) |
| Dec 2002 | -$1.01 M(-29.3%) | $26.00 K(-106.1%) | -$1.01 M(+11.4%) |
| Sept 2002 | - | -$425.00 K(+177.8%) | -$905.00 K(+74.4%) |
| June 2002 | - | -$153.00 K(-66.4%) | -$519.00 K(-40.8%) |
| Mar 2002 | - | -$456.00 K(-453.5%) | -$876.00 K(-38.5%) |
| Dec 2001 | -$1.43 M(-63.3%) | $129.00 K(-430.8%) | -$1.43 M(-38.5%) |
| Sept 2001 | - | -$39.00 K(-92.4%) | -$2.32 M(-34.2%) |
| June 2001 | - | -$510.00 K(-49.3%) | -$3.52 M(-12.2%) |
| Mar 2001 | - | -$1.00 M(+31.9%) | -$4.01 M(+3.2%) |
| Dec 2000 | -$3.89 M(+56.9%) | -$762.00 K(-38.6%) | -$3.89 M(+25.3%) |
| Sept 2000 | - | -$1.24 M(+24.1%) | -$3.10 M(+16.6%) |
| June 2000 | - | -$1.00 M(+13.5%) | -$2.66 M(+43.1%) |
| Mar 2000 | - | -$882.00 K(-3934.8%) | -$1.86 M(-24.9%) |
| Dec 1999 | -$2.48 M(-52.4%) | $23.00 K(-102.9%) | -$2.48 M(-36.5%) |
| Sept 1999 | - | -$800.00 K(+300.0%) | -$3.90 M(-13.3%) |
| June 1999 | - | -$200.00 K(-86.7%) | -$4.50 M(-23.7%) |
| Mar 1999 | - | -$1.50 M(+7.1%) | -$5.90 M(+13.5%) |
| Dec 1998 | -$5.20 M(+8.3%) | -$1.40 M(0.0%) | -$5.20 M(+4.0%) |
| Sept 1998 | - | -$1.40 M(-12.5%) | -$5.00 M(-2.0%) |
| June 1998 | - | -$1.60 M(+100.0%) | -$5.10 M(-7.3%) |
| Mar 1998 | - | -$800.00 K(-33.3%) | -$5.50 M(+14.6%) |
| Dec 1997 | -$4.80 M(+11.6%) | -$1.20 M(-20.0%) | -$4.80 M(-2.0%) |
| Sept 1997 | - | -$1.50 M(-25.0%) | -$4.90 M(+14.0%) |
| June 1997 | - | -$2.00 M(+1900.0%) | -$4.30 M(+10.3%) |
| Mar 1997 | - | -$100.00 K(-92.3%) | -$3.90 M(-9.3%) |
| Dec 1996 | -$4.30 M(-18.9%) | -$1.30 M(+44.4%) | -$4.30 M(+2.4%) |
| Sept 1996 | - | -$900.00 K(-43.8%) | -$4.20 M(-10.6%) |
| June 1996 | - | -$1.60 M(+220.0%) | -$4.70 M(-4.1%) |
| Mar 1996 | - | -$500.00 K(-58.3%) | -$4.90 M(-7.5%) |
| Dec 1995 | -$5.30 M(-1425.0%) | -$1.20 M(-14.3%) | -$5.30 M(+20.5%) |
| Sept 1995 | - | -$1.40 M(-22.2%) | -$4.40 M(+69.2%) |
| June 1995 | - | -$1.80 M(+100.0%) | -$2.60 M(+160.0%) |
| Mar 1995 | - | -$900.00 K(+200.0%) | -$1.00 M(-350.0%) |
| Dec 1994 | $400.00 K(-125.0%) | -$300.00 K(-175.0%) | $400.00 K(-42.9%) |
| Sept 1994 | - | $400.00 K(-300.0%) | $700.00 K(-240.0%) |
| June 1994 | - | -$200.00 K(-140.0%) | -$500.00 K(-61.5%) |
| Mar 1994 | - | $500.00 K(>+9900.0%) | -$1.30 M(-18.8%) |
| Dec 1993 | -$1.60 M(+220.0%) | $0.00(-100.0%) | -$1.60 M(-5.9%) |
| Sept 1993 | - | -$800.00 K(-20.0%) | -$1.70 M(+88.9%) |
| June 1993 | - | -$1.00 M(-600.0%) | -$900.00 K(+800.0%) |
| Mar 1993 | - | $200.00 K(-300.0%) | -$100.00 K(-80.0%) |
| Dec 1992 | -$500.00 K(+150.0%) | -$100.00 K(<-9900.0%) | -$500.00 K(+25.0%) |
| Sept 1992 | - | $0.00(-100.0%) | -$400.00 K(0.0%) |
| June 1992 | - | -$200.00 K(0.0%) | -$400.00 K(+100.0%) |
| Mar 1992 | - | -$200.00 K | -$200.00 K |
| Dec 1991 | -$200.00 K | - | - |
FAQ
- What is GT Biopharma annual cash flow from operations?
- What is the all time high annual CFO for GT Biopharma?
- What is GT Biopharma annual CFO year-on-year change?
- What is GT Biopharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for GT Biopharma?
- What is GT Biopharma quarterly CFO year-on-year change?
- What is GT Biopharma TTM cash flow from operations?
- What is the all time high TTM CFO for GT Biopharma?
- What is GT Biopharma TTM CFO year-on-year change?
What is GT Biopharma annual cash flow from operations?
The current annual CFO of GTBP is -$8.85 M
What is the all time high annual CFO for GT Biopharma?
GT Biopharma all-time high annual cash flow from operations is $400.00 K
What is GT Biopharma annual CFO year-on-year change?
Over the past year, GTBP annual cash flow from operations has changed by +$6.37 M (+41.83%)
What is GT Biopharma quarterly cash flow from operations?
The current quarterly CFO of GTBP is -$2.74 M
What is the all time high quarterly CFO for GT Biopharma?
GT Biopharma all-time high quarterly cash flow from operations is $500.00 K
What is GT Biopharma quarterly CFO year-on-year change?
Over the past year, GTBP quarterly cash flow from operations has changed by -$773.00 K (-39.36%)
What is GT Biopharma TTM cash flow from operations?
The current TTM CFO of GTBP is -$12.48 M
What is the all time high TTM CFO for GT Biopharma?
GT Biopharma all-time high TTM cash flow from operations is $700.00 K
What is GT Biopharma TTM CFO year-on-year change?
Over the past year, GTBP TTM cash flow from operations has changed by -$1.38 M (-12.43%)